Sugi Predict

Sugi Predict / Compounds / SCHEMBL5226491

SCHEMBL5226491

SCHEMBL5226491

CC(C)(C)OC(=O)N1CCN2C(=O)N(CC(F)(F)F)C(=O)[C@]2(Cc2ccccn2)C1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 2/20 0.38
▸ GPR119 Q8TDV5 3/20 0.38
▸ USP30 Q70CQ3 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ DTYMK P23919 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.36
▸ GRM5 P41594 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ CKS1B P61024 1/20 0.35
▸ SKP1 P63208 1/20 0.35
▸ SKP2 Q13309 1/20 0.35
▸ CYP11B2 P19099 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228646 1.00 ACHE (0.38) ACHEGPR119USP30POLBDTYMK
SCHEMBL5228930 0.87 KDM4E (0.35) LMNAKDM4EALDH1A1
SCHEMBL7538881 0.83 PDE10A (0.39) ACHEGPR119USP30POLBDTYMK
SCHEMBL5224568 0.81 GPR119 (0.42) ACHEGPR119USP30POLBDTYMK
SCHEMBL6638381 0.78 GHSR (0.39) KDM4EALDH1A1
SCHEMBL5228589 0.78 GHSR (0.45) —
SCHEMBL5230927 0.78 GHSR (0.45) —
SCHEMBL5229201 0.78 GHSR (0.38) —
SCHEMBL6693596 0.78 DTYMK (0.40) ACHEGPR119USP30POLBDTYMK
SCHEMBL7101578 0.77 MC4R (0.38) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 — — EP claimed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 — — US claimed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 — — US claimed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 — — US claimed
US-6429313-B2 Dipeptide derivatives PFIZER INC. 2002-08-06 — — US claimed
US-20020065284-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-05-30 — — US claimed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 — — US claimed
US-20020002165-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-01-03 — — US claimed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 — — US claimed
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 — — EP disclosed
US-6953791-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-11 — — US disclosed
US-6951850-B2 Dipeptide derivatives PFIZER, INC. (US) 2005-10-04 — — US disclosed
US-6924280-B2 Dipeptide derivatives PFIZER INC. (US) 2005-08-02 — — US disclosed
US-RE38524-E1 Dipeptide derivatives as growth hormone secretagogues PFIZER INC. 2004-06-01 — — US disclosed
US-6358951-B1 ADMINISTERING PYRAZOLO(4,3-C)PYRIDINE DERIVATIVE TO TREAT OBESITY, CONGESTIVE HEART FAILURE, OSTEOPOROSIS, AGING, BONE AND MUSCULAR DISORDERS PFIZER INC. 2002-03-19 — — US disclosed
US-20020002165-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-01-03 — — US disclosed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 — — US disclosed
EP-1001970-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 2000-05-24 — — EP disclosed
EP-0995748-A1 Growth hormone secretagogues Pfizer Products Inc. (US) 2000-04-26 — — EP disclosed
WO-1998058947-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 1998-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR ACHE 3514/4885GPR119 59/4885USP30 2135/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3808/4885GPR119 53/4885USP30 1692/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 4103/4885GPR119 55/4885USP30 1452/4885
US-20020002165-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3808/4885GPR119 53/4885USP30 1692/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3741/4885GPR119 40/4885USP30 1467/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3808/4885GPR119 53/4885USP30 1692/4885
US-20020065284-A1 Dipeptide derivatives GIPR, GHRHR, GHSR ACHE 3808/4885GPR119 53/4885USP30 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.